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Background: The BODE index was recently validated as a multidimensional tool for the 
evaluation of patients with COPD. The inﬂ  uence of gender on the BODE index has not been 
studied.
Hypothesis: The contribution of each component of the disease to the BODE index may differ 
according to gender. 
Methods: We evaluated age, forced expiratory volume in one second (FEV1), Modiﬁ  ed Medical 
Research Council (MMRC) score, 6-min walk distance (6MWD), and body mass index (BMI) 
in 52 men and 52 women with COPD and the same BODE index. We compared the studied 
parameters between men and women and then performed a multiple regression analysis by 
gender.
Results: We found statistically signiﬁ  cant differences between men and women in all param-
eters: FEV1 % (55 ± 17 vs 63 ± 18, p < 0.001), MMRC [1 (0–2) vs 1 (1–2) p = 0.03], BMI [28 
(26–30) vs 25 (22–30), p = 0.05], and 6MWD [546 (451–592) vs 462 (419–520), p = 0.001]. 
Multiple regression analysis revealed that each component of the BODE index had different 
weight (β standardized coefﬁ  cient) in men and women respectively: FEV1% (0.74 vs 0.62), 
MMRC (0.31 vs 0.48), BMI (–0.09 vs –0.17), and 6MWD (0.13 vs 0.10). 
Conclusions: The contribution of each component to the BODE index differs by gender in 
subjects with similar BODE scores. Long term longitudinal studies will help determine the 
signiﬁ  cance of our ﬁ  ndings. 
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Introduction
Chronic Obstructive Pulmonary Disease (COPD), is characterized by poorly reversible 
airﬂ  ow limitation and is predicted to be the third leading cause of death world-wide 
by 2020 (Murray and Lopez 1997). According to recent COPD disease surveillance 
in the United States there was a ﬁ  ve-fold increase in female COPD-related mortality 
between 1971 and 2000 and in 2000 for the ﬁ  rst time, more women died from COPD 
than men (Mannino et al 2002). 
The risk of death in patients with COPD is often graded with the use of a single 
physiological variable, the forced expiratory volume in one second (FEV1) (Siafakas 
et al 1995). However, a multidimensional evaluation of disease severity and progno-
sis: the BODE index (Body mass index, degree of airway Obstruction, Dyspnea and 
Exercise capacity) has been recently validated in a population of predominantly male 
COPD patients as a better independent predictor of respiratory and overall mortality 
than FEV1 % (Celli et al 2004). Another study (Celli et al 2005) of 816 patients with 
COPD investigating the prognostic signiﬁ  cance of 40 potential staging variables identi-
ﬁ  ed 3 key elements of a multidimensional grading system that proved to be useful in 
the evaluation of the disease. International Journal of COPD 2007:2(2)  152
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We have recently identiﬁ  ed gender differences in the 
clinical presentation of the disease in FEV1% matched 
populations (de Torres et al 2005). We also observed that 
the main components of the disease evaluated by the BODE 
index (body mass index [BMI], Modiﬁ  ed Medical Research 
Council [MMRC], and 6-min walk distance [6MWD]) were 
different in men and women.
We therefore postulated that the relative weight each com-
ponent has on the total BODE score could differ by gender. 
To prove this hypothesis we planned this cross sectional 
comparative study of 52 men and 52 women with the same 
BODE index and investigated the relative contribution of 
each of the components to the total BODE index. 
Methods
This matched case series study, recruited women and 
men with COPD attending an outpatient pulmonary clinic 
at Hospital Universitario Ntra Sra de Candelaria; a tertiary 
referral center in Santa Cruz de Tenerife, Spain from January 
2000 to March 2006. Patients with any degree ofseverity 
were included if they had smoked ≥10 pack years, and had 
a post-bronchodilator FEV1/forced vital capacity (FVC) of 
< 0.7 after 400 μg of inhaled albuterol. Patients were excluded 
if they had a history of asthma, bronchiectasis, tuberculosis, 
or other confounding diseases. The patients were clinically 
stable (no exacerbations for at least 2 months) at the time 
of the evaluation and were part of the BODE international 
multicenter study (Celli et al 2004). The Institutional Ethics 
Committee approved the study, and all patients signed an 
informed consent. 
We evaluated the following parameters in the study 
sample: age, spirometry (FEV1, FVC, FEV1/FVC), dyspnoea 
by the MMRC, BMI (weight in kilograms divided by height 
in meters2), and the 6MWD test. Postbronchodilator FEV1% 
of predicted, FVC% of predicted and FEV1/FVC values were 
determined using the European Community for Steel and Coal 
reference values for Spain (Quanjer 1983) and using a Jaegger 
920 MasterLab® Body Box. The MMRC (Brooks 1982) is a 
dyspnoea scale that ranges from 0 (dyspnoea only with intense 
physical activity), to 4 (dyspnoea with minimal activity such 
as getting dressed). The 6MWD test was performed according 
to published ATS recommendations (ATS 2002).
Patients were matched from an initial sample of 111 
males and 52 females with COPD. We were able to match 
every female patient with a corresponding male with identi-
cal BODE index. When more than one male matched, we 
randomly chose the patient to be included in the ﬁ  nal sample. 
A blinded investigator performed case matching.  
Statistical analysis
We describe each variable using mean ± SD or median (25th 
percentile-75th percentile) depending on distribution. We 
compared differences between men and women with student 
t test or Mann-Whitney´s U test depending on distribution. 
We then performed a multiple regression analysis with 
BODE index as the dependent variable and those parameters 
included in the index as predictors. A p value ≤ 0.05 was con-
sidered statistically signiﬁ  cant. The analysis was performed 
with SPSS® (software version 12, Chicago, IL, USA).
Results
The clinical characteristics of the patients participating in 
the study are described in Table 1. Female participants were 
younger, had better lung function, higher dyspnoea scores, 
and worse nutritional status and exercise capacity than men. 
The distribution of patients classiﬁ  ed by the GOLD staging 
system was gender dependent, but no differences were found 
in the classiﬁ  cation by BODE index quartiles. 
Table 2 shows a description of the variables and points 
values used for the computation of the BODE index. Table 3 
shows the results of the lineal regression analysis by gender 
with BODE index as the dependent variable and its com-
ponents as independent predictors of its score. There were 
gender differences in the relative weight that each component 
of the BODE index had on the total score. This is shown in 
Figure 1 where each component represents the percentage of 
the total BODE score. MMRC and BMI contributed most to 
the overall score in women, while FEV1% and 6MWD were 
more signiﬁ  cant in men. 
Discussion
COPD is now considered a respiratory disease with important 
systemic consequences (Agusti et al 2003). Several studies 
have shown that there are different independent clinical 
parameters that help predict survival in patients with COPD 
(Anthonisen et al 1986; Nishimura et al 2002; Pinto-Plata 
et al 2004; Vestbo et al 2005). This independent relationship 
has been conﬁ  rmed in a factor analysis performed in a large 
cohort of patients. Indeed, the FEV1, degree of dyspnoea, and 
exercise capacity, provide independent information regarding 
the degree of compromise in patients with COPD (Ries et al 
1991). Recently Celli and colleagues (2004) combined these 
three variables with BMI and developed a multi-dimensional 
score reﬂ  ecting 3 important dimensions of the disease: airﬂ  ow 
limitation (FEV1%), symptoms (MMRC), and systemic 
manifestations (BMI and 6MWD). The BODE index predicts 
respiratory and overall mortality better than FEV1. These International Journal of COPD 2007:2(2)  153
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ﬁ  ndings suggest that the clinical evaluation of all patients 
with COPD should include the BODE index. Unfortunately, 
one important limitation recognized in the Celli study was 
the small number of women participants (only 17 patients out 
of 625). Therefore, including the BODE index as an integral 
part of the evaluation of female patients with COPD is ques-
tionable. Another recent study by a group of experts in the 
disease (Celli et al 2005) studied over 40 potential staging 
variables in a population of 816 COPD patients participat-
ing in drug trials, evaluating them according to sensitivity to 
change, measured reproducibly, independence of the infor-
mation they provide, and prognostic value. They performed 
principal component analysis and identiﬁ  ed 6 independent 
groups: pulmonary function (including FEV1), symptoms of 
cough and sputum, dyspnoea, health status, bronchodilator 
reversibility, and BMI. They selected 3 variables (FEV1, 
MMRC, and BMI) and elaborated a multidimensional score 
that proved to be useful in predicting outcome. 
We have recently found (de Torres et al 2005) that men 
and women with the same FEV1% show differences in the 
clinical presentation of the disease. We found signiﬁ  cant dif-
ferences in all the components of the BODE index. Women 
had worse dyspnoea, exercise capacity, and nutritional status 
at an earlier stage of the disease. 
Our present study shows that the proportional weight 
of each component over the total score of the index differs 
in men and women with COPD. Furthermore, the order 
of importance of these domains is not the same in the two 
genders. The individual weight of each variable was gen-
der speciﬁ  c: the contribution of FEV1% and 6MWD was 
Table 1 Clinical characteristics of patients
Clinical parameter  Men (n = 52)  Women (n = 52)  p Value
Age (yrs)  63 ± 8  55 ± 11  < 0.001*
FEV1% of predicted  55 ± 17  63 ± 18  0.03*
FVC % of predicted  86 ± 17  93 ± 23  0.03*
FEV1/FVC  50 ± 10  56 ± 10  0.005*
MMRC (points)  1 (0–2)  1 (1–2)  0.035*
BMI (Kg/m2)  28 (26–30)  25 (22–30)  0.05*
6MWD (m)  546 (451–592)  462 (419–520)  0.001*
GOLD Stage (%)
I 7  19  0.32
II 54  54
II 33  25
IV 6  2
BODE quartiles (%)
1st (0–2)  71  71  0.78
2nd(3–4) 25 25   
3rd(5–6) 4  4
4th(7–10) 0  0
Note: Expressed as mean ± SD or median (25–75th percentiles); p ≤ 0.05 considered statistically signiﬁ  cant.
Abbreviations: BMI, body mass index; BODE, Body mass index, degree of airway Obstruction, Dyspnea and Exercise capacity; GOLD, global obstructive lung disease; FEV1, 
forced expiratory volume in one second; FVC, forced vital capacity; MMRC, Modiﬁ  ed Medical Research Council; SD, standard deviation; 6MWD, 6-minute walk distance.  
Table 2 Variables and points values used for the computation of 
the BODE index
Variable  Points of BODE index
  0 1  2  3
FEV1% of predicted  ≥65 50–64 36–49  ≤35
6MWD (m)  ≥350 250–349  150–249  ≤149
MMRC   0–1  2  3  4
BMI >21  ≤21
Note: Total possible values range from 0 to 10.
Abbreviations: BMI, body mass index; BODE, Body mass index, degree of airway 
Obstruction, Dyspnea and Exercise capacity; FEV1, forced expiratory volume in 
one second; MMRC, Modiﬁ  ed Medical Research Council; 6MWD, 6-minute walk 
distance.
Table 3 Results of the lineal regression analysis by gender with 
BODE index
Variable Men Women
FEV1% 0.75  0.62
MMRC 0.30  0.49
BMI –0.09  –0.17
6MWD 0.13  0.11
Note: R2=0.98 for men and R2=0.99 for women; All standardized coefﬁ  cients with 
p < 0.001.
Abbreviations: BMI, body mass index; BODE, Body mass index, degree of airway 
Obstruction, Dyspnea and Exercise capacity; FEV1, forced expiratory volume in 
one second; MMRC, Modiﬁ  ed Medical Research Council; 6MWD, 6-minute walk 
distance.International Journal of COPD 2007:2(2)  154
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greater in men while MMRC and BMI had a greater impact 
in women’s BODE indices. This ﬁ  nding is very interest-
ing because it might imply fundamental differences in the 
expression and perception of respiratory disease in men and 
women. This observation supports the need to adequately 
assess every dimension of COPD beyond respiratory impair-
ment. In addition, the results support the use of the BODE 
index, because it takes into account respiratory symptoms 
and the systemic implications of this illness beyond airﬂ  ow 
limitation incorporating them into a single expression of 
important clinical value. 
The BODE index addresses gender speciﬁ  c limitations of 
spirometry or the GOLD (Global Obstructive Lung Disease) 
classiﬁ  cation which are heavily dependent on the severity of 
airﬂ  ow limitation and largely ignore symptoms and systemic 
consequences of COPD such as nutritional status. Indeed, 
while classiﬁ  cation of disease severity based on airﬂ  ow limita-
tion might be best suited to male patients with COPD, we run 
the risk of underestimating the burden of disease in female 
patients by ignoring the important contribution of BMI and 
dyspnoea in these patients. Reliance on the BODE index helps 
address these issues by incorporating those other domains that 
are more frequently altered in women with the disease. 
The importance of nutritional status in patients with 
COPD has been reported. Mortality sharply increases when 
BMI falls below 21 (Vestbo et al 2005). We found lower 
BMIs for a given BODE score in female patients when 
compared with their matched male controls. In fact, BMI had 
greater relative weight in women over the total BODE index 
score than men. This implies that a nutritional evaluation 
is especially important in women with COPD, and should 
be included alone or integrated in a composite index in the 
standard assessment of female patients with this disease. 
Our women with COPD walked a shorter distance in 
the 6MWD test. This ﬁ  nding has been previously reported 
elsewhere (Celli et al 2005). When we take into consid-
eration their predictive values according to the European 
predictive equation (Troosters et al 1999) we see that these 
fall within the normal range for both men and women. The 
novel ﬁ  nding of the present study was the greater relative 
importance that this has in the multisystemic component of 
the disease in men.  
The main limitation of our study is its cross-sectional 
design. We still do not know how the different quartiles of 
the BODE index reflect the evolution and survival of the 
disease in a population of women with COPD. Further-
more, we do not know whether interventions shown to im-
prove the BODE index and survival of male patients with 
COPD such as lung volume reduction surgery (LVRS) 
(Imfeld et al 2006) or pulmonary rehabilitation (Cote and 
Celli 2005), have the same effects in women. Another 
limitation is that our study includes patients mainly in 
GOLD stages II and III or in the lower quartiles of the 
BODE index. We do not know if the same findings apply 
to other populations not included in this study, including 
patients with higher BODE indices.  
In conclusion, we have demonstrated that the relative 
weight of each component of the BODE index differs by 
gender. Perception of disease and nutritional status has a 
more important role in women with COPD when a multidi-
mensional evaluation of the disease is performed. We believe 
the BODE index, might be particularly useful in assessing 
COPD severity in women because it takes into account those 
aspects of the disease most relevant to this population for a 
given degree of airﬂ  ow obstruction. Since the BODE index 
was validated primarily in a population of men with COPD, 
Figure 1 Percentage of relative weight of each of the parameters over the total BODE index. 
Abbreviations: BMI, body mass index; BODE, Body mass index, degree of airway Obstruction, Dyspnea and Exercise capacity; FEV1, forced expiratory volume in one 
second; MMRC, Modiﬁ  ed Medical Research Council; 6MWD, 6-minute walk distance.
MEN WOMEN
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one can only hope that future longitudinal studies might 
prove it to be even more useful in the evaluation of women 
with COPD.  
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